Pizana v. Sanmedica International LLC

District Court, E.D. California·Decided October 15, 2020·No. 1:18-cv-00644·Unknown

Opinion

RAUL PIZANA, individually and on No. 1:18-cv-00644-DAD-SKO behalf of all others similarly situated, Plaintiff, ORDER RE: PLAINTIFF’S MOTION TO v. COMPEL AND DEFENDANT’S MOTIONS SANMEDICA INTERNATIONAL, LLC, and DOES 1 through 10, inclusive, (Docs. 82, 83, & 84) Defendants. This matter is before the Court on Plaintiff Raul Pizana (“Plaintiff”)’s motion to compel discovery responses (Doc. 82) and Defendant SanMedica International, LLC (“Defendant”)’s motions for protective order (Docs. 83 & 84). Plaintiff and Defendant filed their joint statements directed to the motions, as required by this Court’s Local Rule 251, on September 16, 2020. (Docs. 89, 90, & 91.) The Court reviewed the parties’ papers and all supporting material and found the matter suitable for decision without oral argument. The hearing set for September 23, 2020, was therefore vacated. (Doc. 94.) Having considered the parties’ briefing, and for the reasons set forth below, Plaintiff’s motion to compel (Doc. 82) will be granted in part and denied in part, and Defendant’s motions for protective order (Docs. 83 & 84) will be granted and denied, respectively. Plaintiff Raul Pizana filed this putative class action on May 9, 2018, challenging the advertising and efficacy of SeroVital-hgh (the “Product”), a purported Human Growth Hormone (“HGH”) supplement produced by Defendant that was purchased by Plaintiff in early 2017. (Doc. 53, Second Am. Compl. (“SAC”) at ¶¶ 1, 6, 9.) The Second Amended Complaint, filed on November 13, 2019, asserts three causes of action: (1) a violation of California Civil Code § 1750, et. seq., the Consumer Legal Remedies Act (“CLRA”); (2) a violation of California Business & Professions Code § 17500, et. seq., the False Advertising Law (“FAL”); and (3) a violation of California Business & Professions Code § 17200, et. seq., the Unfair Competition Law (“UCL”). (SAC at ¶¶ 60–121.). The crux of Plaintiff’s suit is that Defendant’s Product, despite being marketed as an HGH supplement that can “make users look and feel decades—not years, but DECADES— younger,” is “no more effective for its advertised purposes than a placebo[] and is therefore worthless to California consumers[.]” (SAC at ¶¶ 1–5.) Specifically, Plaintiff alleges: (1) [T]he Product cannot increase HGH levels whatsoever, let alone by 682%; (2) the Product does not reduce wrinkles, “decrease[] body fat,” “increase[] lean muscle mass,” strengthen bones, “improve[] mood,” “heighten[] sex drive,” or make “users look and feel decades … younger” because the oral administration of amino acids like SeroVital does not increase growth hormone bioactivity; (3) there is no causal link between increased HGH levels and most of the claimed uses, including wrinkle reduction, increased lean muscle mass, stronger bones, improved mood, [or] heightened sex drive; and (4) if SeroVital were to increase HGH levels as claimed, it would cause significant health risks. (Id. at ¶ 2.) Plaintiff seeks to assert claims on behalf of a proposed class defined as: All persons residing in California who purchased the Product for personal use and not for resale during the time period May 9, 2014, through the present. Excluded from the Class are Defendant’s officers, directors, and employees, and any individual who received remuneration from Defendant in connection with that individual’s use or endorsement of the Product. (SAC ¶ 50.) On March 6, 2020, the Court entered a scheduling order that bifurcated merits from class certification discovery and set a deadline of December 18, 2020, for class discovery only.1 (See Doc. 74.) Plaintiff moves to compel: (1) discovery of information pertaining to the identification of 1 The parties agreed in their joint scheduling report that discovery in this case should be bifurcated. (See Doc. 71 at 5.) the members of the putative class (Plaintiff’s First Set of Requests for Production (“RFPs”) No. 36 & 37); (2) further responses to discovery requests for Product advertising, labeling, marketing, and packaging (Plaintiff’s First Set of Interrogatories (“Interrogatories”) No. 2 & 4 and RFPs No. 7–12, 14, & 16–24); (3) production of documents concerning Defendant’s market research for the Product, including consumer surveys and documents relating to the “target market” and “consumer demographic” for the Product (RFPs No. 41–42 & 45–46); and (4) identification of each document responsive to Interrogatory No. 10 and of documents produced in response to RFPs. (See Doc. 82; Doc. 91 at 11–62.) Defendant seeks protective orders (1) relieving Defendant of its obligation pursuant to Rule 30(b)(6) to designate a witness to testify regarding the identification of members of the putative class (Deposition Topic No. 22) (see Doc. 84; Doc. 89 at 3–7); and (2) limiting Plaintiff’s questioning at the deposition of Defendant’s corporate representative, designated pursuant to Fed. R. Civ. P. 30(b)(6), about the Product’s marketing materials, advertisements, labels, and packaging (Deposition Topics No. 5–7 & 10–13) to the putative class period (see Doc. 83; Doc. 90 at 4–6). A. Discovery Generally Federal Rule of Civil Procedure 26(b)(1) provides that parties [m]ay obtain discovery regarding any nonprivileged matter that is relevant to any party’s claim or defense and proportional to the needs of the case, considering the importance of the issues at stake in the action, the amount in controversy, the parties relative access to relevant information, the parties’ resources, the importance of the discovery in resolving the issues, and whether the burden or expense of the proposed discovery outweighs its likely benefit. Fed. R. Civ. P. 26(b)(1). “The party seeking to compel discovery has the burden of establishing that its request satisfies the relevancy requirements of Rule 26(b)(1). Thereafter, the party opposing discovery has the burden of showing that the discovery should be prohibited, and the burden of clarifying, explaining or supporting its objections.” Bryant v. Ochoa, No. 07cv200 JM (PCL), 2009 WL 1390794, at *1 (S.D. Cal. May 14, 2009) (citations omitted). Motions for protective orders are governed by Federal Rule of Civil Procedure 26(c), which states in relevant part: A party or any person from whom discovery is sought may move for a protective order in the court where the action is pending[.] The motion must include a certification that the movant has in good faith conferred or attempted to confer with other affected parties in an effort to resolve the dispute without court action. The court may, for good cause, issue an order to protect a party or person from annoyance, embarrassment, oppression, or undue burden or expense[.] Fed. R. Civ. P. 26(c). District courts have broad discretion to determine whether a protective order is appropriate and, if so, what degree of protection is warranted. Seattle Times Co. v. Rhinehart, 467 U.S. 20, 36 (1984); see also Phillips ex rel. Estates of Byrd v. Gen. Motors Corp., 307 F.3d 1206, 1211–12 (9th Cir. 2002). The party seeking to limit discovery has the burden of proving “good cause,” which requires a showing “that specific prejudice or harm will result” if the protective order is not granted. In re Roman Catholic Archbishop of Portland in Oregon, 661 F.3d 417, 424 (9th Cir. 2011) (citing Foltz v. State Farm Mut. Auto. In

Free access — add to your briefcase to read the full text and ask questions with AI

Pizana v. Sanmedica International LLC, (E.D. Cal. 2020).

Pizana v. Sanmedica International LLC (Pizana v. Sanmedica International LLC) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Gulf Oil Co. v. Bernard
452 U.S. 89 (Supreme Court, 1981)
Seattle Times Co. v. Rhinehart
467 U.S. 20 (Supreme Court, 1984)
Regan-Touhy v. Walgreen Co.
526 F.3d 641 (Tenth Circuit, 2008)
Phillips v. General Motors Corporation
307 F.3d 1206 (Ninth Circuit, 2002)
Vinole v. Countrywide Home Loans, Inc.
571 F.3d 935 (Ninth Circuit, 2009)
Koo v. Rubio's Restaurants, Inc.
135 Cal. Rptr. 2d 415 (California Court of Appeal, 2003)
Belaire-West Landscape, Inc. v. Superior Court
57 Cal. Rptr. 3d 197 (California Court of Appeal, 2007)
Putnam v. Eli Lilly and Co.
508 F. Supp. 2d 812 (C.D. California, 2007)
In re NJOY, Inc. Consumer Class Action Litigation
120 F. Supp. 3d 1050 (C.D. California, 2015)
DIRECTV, Inc. v. Trone
209 F.R.D. 455 (C.D. California, 2002)
Moses v. Halstead
236 F.R.D. 667 (D. Kansas, 2006)
Artis v. Deere & Co.
276 F.R.D. 348 (N.D. California, 2011)
Ogden v. Bumble Bee Foods, LLC
292 F.R.D. 620 (N.D. California, 2013)
Gorrell v. Sneath
292 F.R.D. 629 (E.D. California, 2013)